IC
NMRA icon

Iconiq Capital’s Neumora Therapeutics NMRA Stock Holding History

Iconiq Capital’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.99M Hold
2,559,090
– – 0.11% 37
2025
Q4 		$4.58M Hold
2,559,090
– – 0.07% 42
2025
Q3 		$4.66M Hold
2,559,090
– – 0.06% 46
2025
Q2 		$1.88M Hold
2,559,090
– – 0.03% 63
2025
Q1 		$2.56M Hold
2,559,090
– – 0.05% 53
2024
Q4 		$27.1M Sell
2,559,090
-839,538
-25% -$10.1M 0.42% 21
2024
Q3 		$44.9M Hold
3,398,628
– – 0.96% 12
2024
Q2 		$33.4M Hold
3,398,628
– – 0.72% 14
2024
Q1 		$46.7M Hold
3,398,628
– – 0.81% 11
2023
Q4 		$57.9M Buy
+3,398,628
New +$41.7M 1.08% 11

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $120M AUM 72.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Iconiq Capital's NMRA Position: Q1 2026 in Review

Iconiq Capital held its Neumora Therapeutics (NMRA) position steady in Q1 2026 at 2,559,090 shares worth $4.99M. The position accounts for 0.11% of the portfolio, ranked #37.

Iconiq Capital first reported a position in NMRA in Q4 2023 and has held it in 10 quarters since. The position peaked at $57.9M in Q4 2023. 114 funds tracked by Wall St. Rank hold NMRA as of Q1 2026.

  • Iconiq Capital held 2,559,090 shares of Neumora Therapeutics worth $4.99M as of Q1 2026.
  • Iconiq Capital left its Neumora Therapeutics share count unchanged in Q1 2026.
  • Neumora Therapeutics made up 0.11% of Iconiq Capital's portfolio in Q1 2026, its #37 holding.
  • Iconiq Capital first reported a position in Neumora Therapeutics in Q4 2023 and has held it in 10 quarters since.
  • Iconiq Capital's Neumora Therapeutics position peaked at $57.9M in Q4 2023.
  • 114 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q1 2026.

Based on Iconiq Capital's 13F filing for Q1 2026, filed 15 May 2026.